.Pharmacolibrary.Drugs.V_Various.V04C_OtherDiagnosticAgents.V04CD01_Metyrapone.Metyrapone .Pharmacolibrary.Drugs.V_Various.V04C_OtherDiagnosticAgents.V04CD01_Metyrapone.Metyrapone| name: | Metyrapone | |
| ATC code: | V04CD01 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 750 | mg |
| volume of distribution: | 1.1 | L |
| clearance: | 1500 | mL/min |
| other parameters in model implementation | ||
Metyrapone is an inhibitor of adrenal steroidogenesis by blocking 11-β-hydroxylase, leading to decreased cortisol synthesis. It is primarily used as a diagnostic agent for hypothalamic-pituitary-adrenal (HPA) axis disorders and, less commonly, as a treatment for Cushing's syndrome. It has been used clinically for many years and remains available as a diagnostic drug.
Pharmacokinetic parameters estimated for healthy adults following oral administration; no comprehensive human population PK models published in indexed literature.
Spitz, IM, et al., & Wade, CE (1993). The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics. Acta endocrinologica 128(5) 459–465. DOI:10.1530/acta.0.1280459 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8391196